MA71666A - Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés - Google Patents

Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Info

Publication number
MA71666A
MA71666A MA71666A MA71666A MA71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A
Authority
MA
Morocco
Prior art keywords
scd5
stearoyl
methods
rnai agent
agent compositions
Prior art date
Application number
MA71666A
Other languages
English (en)
Inventor
Adam CASTORENO
James D. Mcininch
Lan Thi Hoang DANG
Original Assignee
Alnylam Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals, Inc. filed Critical Alnylam Pharmaceuticals, Inc.
Publication of MA71666A publication Critical patent/MA71666A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14212Pumping with an aspiration and an expulsion action
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71666A 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés MA71666A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163162788P 2021-03-18 2021-03-18
US202163278389P 2021-11-11 2021-11-11
PCT/US2022/020825 WO2022197975A1 (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés
EP22772237.8A EP4308130A4 (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
MA71666A true MA71666A (fr) 2025-05-30

Family

ID=83320836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71666A MA71666A (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Country Status (4)

Country Link
US (1) US20240200077A1 (fr)
EP (1) EP4308130A4 (fr)
MA (1) MA71666A (fr)
WO (1) WO2022197975A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633770B1 (fr) * 2003-06-13 2015-04-29 Alnylam Europe AG Acide ribonucleique double brin presentant une efficacite accrue dans un organisme
US20070161003A1 (en) * 2003-09-29 2007-07-12 Morris David W Novel therapeutic targets in cancer
NZ594995A (en) * 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
CN103361352A (zh) * 2013-07-31 2013-10-23 扬州大学 鹅原代肝细胞scd1基因沉默试剂盒及其应用
EP3566055B1 (fr) * 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Inhibiteurs de la scd pour le traitement de troubles neurologiques

Also Published As

Publication number Publication date
EP4308130A4 (fr) 2025-09-17
EP4308130A1 (fr) 2024-01-24
WO2022197975A1 (fr) 2022-09-22
US20240200077A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
EP4329757A4 (fr) Composés hétérocycliques et procédés d'utilisation
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
EP3890736A4 (fr) Agents de dégradations de petites molécules de helios et procédés d'utilisation
EP4153564A4 (fr) Dérivés de tryptamine deutérés et procédés d'utilisation
EP4125831A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP4208445A4 (fr) Dérivés de psilocybine halogénés et leurs procédés d'utilisation
EP3969460A4 (fr) Dérivés d'ascaroside et procédés d'utilisation
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
EP4423205A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3996714A4 (fr) Formulations d'inhibiteurs de rbp4 et procédés d'utilisation
EP4297871A4 (fr) Procédés et compositions pour le traitement de l'agitation
EP4161921A4 (fr) Inhibiteurs de traduction du collagène 1 et leurs procédés d'utilisation
EP4319813A4 (fr) Multimères de peptide-mhc-immunoglobuline et leurs procédés d'utilisation
EP4346815A4 (fr) Composés hétérocycliques et procédés d'utilisation
EP4370537A4 (fr) Compositions comprenant des peptides multi-agonistes, procédés de fabrication et méthodes d'utilisation
EP4259178A4 (fr) Compositions et procédés d'extension de demi-vie
MA71666A (fr) Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés
EP4175624A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP4294454A4 (fr) Peptides anti-viraux et compositions et procédés d'utilisation associés
EP3752517A4 (fr) Agents de dégradation de kinase dépendante de la cycline et procédés d'utilisation
MA50798A (fr) Procédés d'utilisation et compositions contenant du dulaglutide